Kumar Neil 4

What Happened
Kumar Neil, a director of BridgeBio Oncology Therapeutics, Inc. (BBOT), was granted a derivative award covering 31,675 shares on June 16, 2026. The reported acquisition price is $0.00 (grant of an equity award/stock option), so no cash changed hands at grant. The grant is reported as transaction code “A” (award/grant).

Key Details

• Transaction date: 2026-06-16; Form 4 filed: 2026-06-18 (filed within the standard two-business-day window).
• Award amount: 31,675 shares (derivative grant); reported acquisition price $0.00.
• Shares owned after transaction: Not specified in this filing.
• Footnote F1: The shares underlying the stock option vest in full on the earlier of (i) the first anniversary of the grant date or (ii) the next Annual Meeting of Stockholders, subject to continued service.
• Filing includes Exhibit 24 (Power of Attorney).

Context
This filing reflects a grant of equity (stock option) to a director rather than a market buy or sell. No exercise or sale occurred — the award vests based on service/time per the footnote. Such grants are common for director compensation and do not by themselves indicate buying or selling sentiment.